{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01764100",
      "OrgStudyIdInfo": {
        "OrgStudyId": "PTC-MSC"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2008-007869-23",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Azienda Ospedaliera San Gerardo di Monza",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)",
      "OfficialTitle": "Mesenchymal Stromal Cells (MSC) for the Treatment of Severe (Grade II-IV) Steroid-resistant Graft Versus Host Disease (GVHD): a Phase I Trial",
      "Acronym": "MSC-GvHD"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2013",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2009"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 2013",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2013",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 5, 2010",
      "StudyFirstSubmitQCDate": "January 7, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 9, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 7, 2013",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 9, 2013",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Ettore Biagi, MD",
        "ResponsiblePartyInvestigatorTitle": "Ettore Biagi, MD",
        "ResponsiblePartyInvestigatorAffiliation": "Azienda Ospedaliera San Gerardo di Monza"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Ettore Biagi, MD",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a bicentric, prospective, non randomized study. Pediatric and adult patients will be treated.\n\nRationale: MSC have shown promising effects by reversal of severe therapy-resistant acute GvHD. As a common therapeutic line of action is not shared for steroid resistant GVHD, it is important to establish the toxicity and the feasibility of preparation and infusion of third party MSCs for acute steroid resistant GVHD and acute phases of chronic steroid resistant GVHD.\n\nA total of 10 patients (pediatric and adults) need to be enrolled in the study. Patients who present clinical signs of either acute or chronic steroid resistant GVHD will receive by intravenous infusion at least two fixed doses of mesenchymal stem cells with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor) regardless of the rate of HLA mismatch.\n\nPrimary objectives are to establish the feasibility and the toxicity of preparation and infusions of third party MSCs for the treatment of steroid resistant acute and acute phases of chronic grade II-IV GVHD.\n\nSecondary objectives are:\n\nTo document the efficacy of MSC infusion in steroid resistant acute and acute phases of chronic GVHD grade II-IV.\nTo document the rate of GVHD recurrence in MSCs infused patients.\nTo document relapse of hematological malignancies post MSC infusions in patients undergoing MSCs treatment for steroid refractory GvHD.\nTo document the overall survival of MSC infused patients for steroid refractory GvHD."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Graft vs Host Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal Stromal Cells (MSC)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Genetic: Mesenchymal stromal cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Genetic",
            "InterventionName": "Mesenchymal stromal cells",
            "InterventionDescription": "Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal Stromal Cells (MSC)"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Any toxic effect reported during MSCs infusion or in the subsequent 10 days by clinical monitoring",
            "PrimaryOutcomeTimeFrame": "During MSCs infusion or in the subsequent 10 days"
          },
          {
            "PrimaryOutcomeMeasure": "Feasibility as the possibility of producing adequate lots of patient dedicated MSCs for any patients presenting with steroid resistant GVHD",
            "PrimaryOutcomeTimeFrame": "three years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of patients with GvHD resolution",
            "SecondaryOutcomeDescription": "Complete resolution of GvHD: Control of all signs and symptoms attributed to acute GvHD\nPartial resolution of GvHD: Control of some signs and symptoms attributed to acute GvHD with an improvement of overall grade\nRefractory GvHD: No change in signs or symptoms of GvHD within 10 days of MSC infusion.\nWorsening GvHD: Any progress of GvHD signs and symptoms that increase overall grade. a and b will be defined as response. c and d will be defined as no response.",
            "SecondaryOutcomeTimeFrame": "One month"
          },
          {
            "SecondaryOutcomeMeasure": "Determination of recurrence of GvHD",
            "SecondaryOutcomeTimeFrame": "After 1 month from MSCs infusion"
          },
          {
            "SecondaryOutcomeMeasure": "Relapse of haematological disease",
            "SecondaryOutcomeTimeFrame": "Every three months"
          },
          {
            "SecondaryOutcomeMeasure": "Survival",
            "SecondaryOutcomeTimeFrame": "Every three months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nInformed consent.\nPatients are required to meet the following inclusion criteria:\n\nAny patient that has undergone allogeneic stem cell transplantation with steroid refractory grades II-IV acute GvHD either occurring post transplant, or induced by donor lymphocyte infusions (DLI) or T-cell add back, or chronic steroid refractory GVHD in acute phase. Patients may be receiving local best treatment for steroid refractory GVHD. A positive biopsy for GvHD is not required if clinical signs and symptoms are characteristic for GvHD and other etiologies are excluded. See 6.4 for acute GvHD grading.\n\nSteroids have been given, for instance methylprednisolone 2 mg/kg/day, for at least 72h in case of progressive acute GvHD, 5 days in case of stable acute GVHD (grade II to IV) or chronic GvHD in active phase, according to the local policy.\nDespite this treatment, the patient has unresponsive GvHD after 5 days, or progressive acute GvHD after 72 hours. If single organ acute GvHD grade II from gut or liver, either progression from single organ or addition of one or two more organs. As an example, if the patient has grade II acute GvHD of the skin, GvHD is more intense and more widespread, or GvHD also includes liver and/or gut.\nPatients with steroid refractory GvHD fulfilling the requirements mentioned in a) - b) may be treated with second line therapy according to the clinical guidelines at each center prior to enrolment in this study.\nPatients under treatment with best available local treatment for steroid resistant GVHD will not interrupt the ongoing treatment unless clinically required for safety reasons.\n\nExclusion Criteria:\n\nInability to obtain informed consent.\nPatients with documented uncontrolled EBV, CMV or fungal infection.\nPatients in poor clinical conditions with life expectancy of less than 30 days.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Ettore Biagi, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+39 039 233",
            "CentralContactPhoneExt": "2232",
            "CentralContactEMail": "e.biagi@hsgerardo.org"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Ettore Biagi, MD",
            "OverallOfficialAffiliation": "San Gerardo Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "U.O. Ematologia - Ospedali Riuniti di Bergamo",
            "LocationStatus": "Recruiting",
            "LocationCity": "Bergamo",
            "LocationState": "BG",
            "LocationZip": "24128",
            "LocationCountry": "Italy",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Alessandro Rambaldi, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "arambaldi@ospedaliriuniti.bergamo.it"
                },
                {
                  "LocationContactName": "Alessandro Rambaldi, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "Clinica Pediatrica CTMO - Azienda Ospedaliera San Gerardo",
            "LocationStatus": "Recruiting",
            "LocationCity": "Monza",
            "LocationState": "MB",
            "LocationZip": "20052",
            "LocationCountry": "Italy",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Ettore Biagi, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "e.biagi@hsgerardo.org"
                },
                {
                  "LocationContactName": "Ettore Biagi, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "U.O. Ematologia CTMO - Azienda Ospedaliera San Gerardo",
            "LocationStatus": "Recruiting",
            "LocationCity": "Monza",
            "LocationState": "MB",
            "LocationZip": "20052",
            "LocationCountry": "Italy",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Matteo Parma, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactEMail": "m.parma@hsgerardo.org"
                },
                {
                  "LocationContactName": "Matteo Parma, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "24321746",
            "ReferenceType": "derived",
            "ReferenceCitation": "Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D'Amico G, Biondi A, Rambaldi A, Biagi E. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014 Mar;20(3):375-81. doi: 10.1016/j.bbmt.2013.11.033. Epub 2013 Dec 7."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft vs Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}